Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 3/20 | 0.31 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592971 | 0.84 | SLC6A4 (0.61) | CYP1A2CYP2D6CYP2C19SLC6A4SLC6A2 | |
| SCHEMBL2316904 | 0.83 | SIGMAR1 (0.47) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL3708454 | 0.82 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL4084298 | 0.81 | MAPK1 (0.46) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL2853081 | 0.81 | CHRM1 (0.41) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL15961230 | 0.79 | SIGMAR1 (0.52) | CYP1A2CYP2D6TSHRCYP2C19SLC6A4 | |
| SCHEMBL17100603 | 0.75 | LMNA (0.35) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL3591699 | 0.75 | FAAH (0.50) | TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL3605151 | 0.74 | FAAH (0.49) | TSHRCYP2C19 | |
| SCHEMBL6100005 | 0.74 | ALDH1A1 (0.48) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | claimed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | claimed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-8435973-B2 | 17-beta HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-1888615-B1 | 17 -HSD1 AND STS INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8030298-B2 | 17β-HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | CYP1A2 236/4885CYP3A4 239/4885CYP2D6 211/4885 |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | CYP1A2 830/4885CYP3A4 1249/4885CYP2D6 958/4885 |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | STS, HSD17B11, HSD17B1 | CYP1A2 92/4885CYP3A4 166/4885CYP2D6 182/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | CYP1A2 1180/4885CYP3A4 1702/4885CYP2D6 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.